Last Updated: November 20, 2026

List of Excipients in Branded Drug CARMUSTINE

« Back to Dashboard


Carmustine Excipient Strategy and Commercial Opportunities

Last updated: October 23, 2026

Carmustine is a high-value formulation target because its commercial use is constrained by chemical instability, poor aqueous stability, cytotoxic handling requirements, and two distinct dosage-form technologies: intravenous powder for reconstitution and a biodegradable intracranial implant. The strongest opportunities are improved injectable reconstitution systems, ready-to-use or extended-stability presentations, safer cytotoxic manufacturing, and next-generation local-delivery implants.

What is the commercial formulation profile of carmustine?

Carmustine, also known as BCNU, is a nitrosourea alkylating agent used in oncology. It is marketed primarily in two formulation classes:

Product type Representative product Delivery route Formulation problem
Injectable powder BiCNU and generic carmustine for injection Intravenous Rapid degradation after aqueous reconstitution
Biodegradable implant Gliadel wafer Intracranial implantation Complex drug-polymer manufacturing and neurosurgical administration

The injectable product is supplied as a sterile lyophilized or powder presentation containing carmustine and dehydrated alcohol. The vial is reconstituted with sterile water and diluted before infusion. The product labeling emphasizes limited stability after reconstitution and the need for controlled handling because carmustine is cytotoxic and chemically unstable in aqueous media (FDA, 2023a).

Gliadel uses polifeprosan 20, a biodegradable polymer matrix composed of polyanhydride-based materials, to deliver carmustine locally after tumor resection. The implant is a drug-device combination product rather than a conventional systemic dosage form (FDA, 2023b).

Which excipients are used in carmustine injection?

The principal excipient strategy for injectable carmustine uses dehydrated alcohol as a nonaqueous solvent and lyophilization or dry-powder presentation to limit hydrolytic degradation.

Dehydrated alcohol

Dehydrated alcohol is central to the conventional injectable formulation. It provides a nonaqueous environment for carmustine before reconstitution and supports the manufacture of a sterile powder or cake. The formulation must balance solvent capacity, residual solvent control, container compatibility, and patient exposure.

Commercial limitations include:

  • Flammability and manufacturing controls.
  • Potential extractables and leachables from elastomeric closures.
  • Patient exposure to ethanol during repeated dosing.
  • Restrictions associated with pediatric, hepatic, or medically fragile populations.
  • Need for validated control of residual alcohol after lyophilization.

A solvent-reduced or solvent-free formulation could create differentiation if it preserves chemical stability and supports a comparable intravenous administration profile.

Sterile water and dextrose dilution

Sterile water is used for initial reconstitution. The resulting solution is diluted in a compatible infusion fluid, commonly 5% dextrose. Aqueous exposure accelerates degradation, making reconstitution time, storage temperature, container material, and infusion duration important product attributes.

The excipient opportunity is not simply to add a stabilizer. Many antioxidants, buffers, surfactants, and chelating agents may affect carmustine degradation, infusion compatibility, or toxicology. Each candidate would require degradation-pathway mapping and impurity qualification.

Potential stabilizer classes

Potential development classes include:

Excipient class Potential role Main development risk
Antioxidants Control oxidative degradation New impurities, compatibility, parenteral safety
Chelators Reduce metal-catalyzed degradation Limited benefit if hydrolysis dominates
Nonionic surfactants Improve wetting or reconstitution Peroxide formation and protein-like impurity concerns
Polyols or sugars Stabilize the dried cake Hygroscopicity and altered reconstitution
Amino acids Modify solid-state stability New degradation pathways and pH effects
Buffer systems Control reconstitution pH May accelerate degradation or reduce solubility
Complexing agents Alter apparent solubility Dose uniformity and regulatory justification

For carmustine, the highest-value excipient work is likely to involve solid-state stabilization and solvent reduction rather than conventional aqueous buffering.

What formulation patents protect carmustine products?

Carmustine patent protection is dosage-form specific. The active ingredient is an older small molecule, so commercial protection depends mainly on formulation, manufacturing, delivery-system, and method-of-use rights.

Injectable formulation patents

Potentially relevant claim categories include:

  • Dry carmustine compositions containing a nonaqueous solvent.
  • Lyophilized carmustine cakes with defined residual solvent limits.
  • Stabilized reconstituted solutions.
  • Container-closure systems that reduce adsorption or degradation.
  • Manufacturing processes for sterile cytotoxic powder.
  • Methods for reducing exposure to degradation products.

The injectable generic pathway is generally expected to focus on pharmaceutical equivalence, bioequivalence or clinical bridging as applicable, sterility, stability, and labeling. A formulation that changes solvent composition, reconstitution instructions, or infusion conditions may move beyond a simple abbreviated new drug application and require a 505(b)(2) strategy.

Gliadel and local-delivery patents

Gliadel-related protection has historically centered on:

  • Carmustine-loaded biodegradable wafers.
  • Polifeprosan 20 composition and molecular characteristics.
  • Drug loading and release profiles.
  • Implant dimensions and mechanical properties.
  • Surgical placement after tumor resection.
  • Local treatment of malignant glioma.

The commercial barrier is not only patent validity. It also includes polymer characterization, reproducible drug loading, controlled release, implant sterility, neurosurgical handling, and combination-product manufacturing.

When does carmustine lose exclusivity?

Carmustine has no meaningful new-molecule exclusivity remaining because it was approved decades ago. Commercial exclusivity depends on product-specific patents, regulatory exclusivities, and the status of listed patents.

Exclusivity category Carmustine position
New chemical entity exclusivity Expired
Orphan-drug exclusivity Product and indication specific; historical periods have expired for older approvals
Injectable generic competition Legally possible subject to listed patents and FDA requirements
Implant competition More difficult because of polymer, device, clinical, and manufacturing barriers
Biosimilar exposure Not applicable; carmustine is a synthetic small molecule
Method-of-use protection May remain relevant where indication or dosing claims are patent-protected

The FDA Orange Book is the primary source for patents and exclusivity listed against approved drug products. Orange Book status must be evaluated separately for the injectable product and the intracranial implant because their sponsors, dosage forms, and regulatory classifications differ (FDA, 2024).

What is the FDA regulatory status of carmustine formulations?

Injectable carmustine

Injectable carmustine is regulated as a conventional drug product. A generic applicant would typically address:

  • Active ingredient identity and assay.
  • Sterility and bacterial endotoxin limits.
  • Particulate matter.
  • Reconstitution time.
  • Solution clarity and color.
  • Degradation products.
  • Residual solvent.
  • Container-closure integrity.
  • Stability under refrigerated and controlled room-temperature conditions.
  • Cytotoxic manufacturing containment.

An improved product with modified excipients could use a 505(b)(2) application if the formulation relies on existing carmustine safety and efficacy data while introducing a material formulation change.

Gliadel wafer

Gliadel is a drug-device combination product. Its development requires control of both the drug and polymer components, including:

  • Polymer molecular-weight distribution.
  • Drug loading uniformity.
  • Release kinetics.
  • Implant geometry.
  • Mechanical handling characteristics.
  • Sterility assurance.
  • Biodegradation products.
  • Local tissue exposure.
  • Surgical placement and handling.

A competing product would face a more demanding comparability assessment than an ordinary injectable generic.

What excipient strategy offers the strongest commercial opportunity?

1. Solvent-reduced injectable carmustine

A lower-ethanol presentation could address handling and tolerability concerns. The target product would maintain a dry state during storage while reducing or eliminating the need for dehydrated alcohol.

Possible approaches include:

  • Alternative nonaqueous solvents.
  • Co-processed solid dispersions.
  • Spray-dried carmustine particles.
  • Amorphous solid dispersions.
  • Protected crystalline forms.
  • Dual-chamber vials separating carmustine from reconstitution fluid.

The primary commercial advantage would be a differentiated label with simplified preparation or lower solvent exposure.

2. Extended-stability reconstituted solution

A formulation that remains usable for a longer period after reconstitution could reduce pharmacy waste and improve hospital workflow. The product would need demonstrated control of potency, impurities, particulate formation, and sterility throughout the proposed hold period.

This opportunity has commercial value because cytotoxic oncology products are often prepared in centralized pharmacy operations, where short in-use stability creates operational waste.

3. Ready-to-use or dual-chamber presentation

A dual-chamber vial, cartridge, or closed-system transfer device could separate dry carmustine from the diluent until administration. The product would combine formulation protection with occupational-safety benefits.

The main IP opportunities would involve:

  • Chamber architecture.
  • Breakable seals.
  • Reconstitution mechanism.
  • Cytotoxic containment.
  • Compatibility of elastomers and plastics.
  • Automated pharmacy compounding.

This approach may be more defensible than a simple excipient substitution because it creates device and process claims.

4. Improved biodegradable implant

A next-generation implant could compete through release control, handling, or surgical convenience rather than only through carmustine content.

Potential design targets include:

  • More predictable release over the post-resection treatment window.
  • Lower burst release.
  • Improved wafer flexibility.
  • Reduced implantation time.
  • Better conformance to irregular resection cavities.
  • Reduced inflammatory response.
  • Combination loading with another local therapy, subject to regulatory and patent constraints.

Polymer selection is the central excipient decision. Candidate matrices must maintain carmustine stability during manufacturing, storage, sterilization, and implantation while producing controlled local release.

5. Injectable nanoparticle or depot systems

Nanoparticles, liposomes, and in situ depots could improve tumor exposure or alter systemic pharmacokinetics. These systems have technical appeal but higher regulatory risk.

Key barriers include:

  • Low payload efficiency for a reactive alkylating agent.
  • Particle-size control.
  • Sterilization.
  • Long-term physical stability.
  • Release testing.
  • Local and systemic toxicity.
  • Complex bioequivalence requirements.

These platforms are more suitable for a novel formulation program than for a rapid generic-entry strategy.

How strong is the carmustine patent estate?

The estate is likely strongest around the implant and weakest around the underlying active ingredient. A practical strength assessment is:

Asset area Relative barrier Main reason
Carmustine molecule Low Old active ingredient
Conventional injectable composition Low to moderate Generic substitution and prior-art exposure
Stabilized injectable formulation Moderate Depends on unexpected stability and narrow claim scope
Dual-chamber or closed-system presentation Moderate to high Device and process differentiation
Polifeprosan-based implant High Polymer, drug loading, release, and manufacturing complexity
New local-delivery polymer Moderate to high Potentially strong composition and use claims
Combination therapy High but uncertain Clinical proof and obviousness risks

Patent strength will depend on claim breadth, enablement, experimental stability data, prior-art disclosure, and whether the claims cover commercially necessary product attributes.

Which companies are challenging or competing with carmustine products?

Competition is divided between generic injectable manufacturers and specialized oncology companies capable of producing implantable drug-device products.

Injectable competition

Potential competitors include manufacturers with:

  • Sterile cytotoxic powder capability.
  • Lyophilization infrastructure.
  • High-containment oncology manufacturing.
  • Established hospital-distribution channels.
  • Experience with abbreviated applications for injectable drugs.

The injectable market is more exposed to price competition because manufacturing technology is familiar and the active ingredient is old.

Implant competition

Implant competition is narrower. A developer would need polymer science, controlled-release manufacturing, neurosurgical clinical development, and combination-product regulatory expertise. This reduces the number of credible entrants but increases development cost and execution risk.

No biosimilar pathway applies. Carmustine is a synthetic small molecule, so competitive entry occurs through generic or hybrid regulatory pathways rather than biosimilar approval.

What generic launch scenarios exist for carmustine?

Scenario 1: Conventional injectable generic

This is the fastest path where no blocking patent or regulatory issue prevents approval. The product competes mainly on supply reliability, price, shortage resilience, and hospital contracting.

Scenario 2: Differentiated injectable

A solvent-reduced, extended-stability, or closed-system product can support a premium or protected niche. The regulatory pathway may be more complex than a standard generic, but the commercial position is stronger.

Scenario 3: Implant competitor

A wafer or depot competitor faces the highest technical and clinical burden. Success requires proof of comparable local delivery, safety, release performance, and surgical usability.

Scenario 4: New indication or local-delivery product

A new formulation tied to a specific tumor type, surgical protocol, or combination regimen could obtain method-of-use protection. The commercial return depends on clinical differentiation and reimbursement.

What manufacturing and IP barriers affect commercial entry?

The most important barriers are:

  1. Chemical instability during aqueous exposure.
  2. Cytotoxic containment and operator protection.
  3. Sterile powder or lyophilized-product processing.
  4. Residual solvent and degradation-product control.
  5. Polymer-drug compatibility for implants.
  6. Reproducible release testing.
  7. Container-closure integrity.
  8. Specialized hospital preparation requirements.
  9. Patent claims covering formulation or local delivery.
  10. FDA requirements for combination products.

The manufacturing barrier is materially higher for Gliadel-type implants than for injectable carmustine. The IP barrier follows the same pattern.

How does carmustine compare with competing oncology delivery systems?

Attribute Carmustine injection Carmustine implant Liposomal or nanoparticle oncology products
Formulation complexity Moderate High High
Excipient dependence Solvent and dry-state control Polymer matrix Lipid or polymer carrier
Stability challenge High High High
Generic substitution More feasible Difficult Usually difficult
Device involvement Low High Low to moderate
Local tumor exposure Low High Variable
Development cost Lower Higher Higher
Patent differentiation Moderate High High

Key Takeaways

  • Carmustine’s core commercial problem is chemical instability, especially after aqueous reconstitution.
  • Dehydrated alcohol and dry-state processing are central to the conventional injectable product.
  • The most attractive injectable opportunities are solvent reduction, longer post-reconstitution stability, and closed-system administration.
  • Gliadel-type products have stronger technical and commercial barriers because they combine carmustine with a biodegradable polymer implant.
  • Carmustine has no biosimilar pathway; competition comes through generic and 505(b)(2) strategies.
  • Formulation, polymer, manufacturing, device, and method-of-use patents matter more than patents on the old active ingredient.
  • The strongest differentiated opportunity is a stable, safer-to-handle product that reduces pharmacy waste or improves local intracranial delivery.

FAQs

Is carmustine water soluble?

Carmustine is unstable in aqueous solution. Its injectable presentation uses a dry or nonaqueous formulation strategy, followed by controlled reconstitution and dilution.

Which excipient is most important in carmustine injection?

Dehydrated alcohol is the key conventional excipient because it supports the nonaqueous formulation before reconstitution. Dry-state stabilization and container compatibility are also critical.

Can carmustine be formulated as a ready-to-use infusion?

A ready-to-use product is technically possible but would require strong control of degradation, impurities, sterility, particulate matter, and in-use stability. A dual-chamber presentation may be more practical than long-term storage of an aqueous infusion.

Is Gliadel a generic drug or a combination product?

Gliadel is a drug-device combination product because carmustine is incorporated into a biodegradable polymer wafer for intracranial implantation.

What is the best commercial excipient opportunity for carmustine?

The strongest opportunity is a differentiated formulation that combines dry-state stability with simplified, closed-system reconstitution or improved local-release performance.

References

  1. U.S. Food and Drug Administration. (2023a). BiCNU (carmustine for injection) prescribing information.
  2. U.S. Food and Drug Administration. (2023b). Gliadel wafer (polifeprosan 20 with carmustine implant) prescribing information.
  3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
  4. U.S. Food and Drug Administration. (2024). Drug approval package: Gliadel wafer.
  5. National Cancer Institute. (2024). Carmustine. NCI Drug Dictionary.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.